NCT07106827 - A Study of GV20-0251 in Advanced or Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

June 11, 2027

Study Completion Date

June 11, 2028

Conditions

HCC - Hepatocellular CarcinomaCholangiocarcinomaMelanomaNSCLC (Non-small Cell Lung Cancer)Pancreatic Ductal AdenocarcinomaHNSCCEndometrial CancerTesticular Cancer

Interventions

DRUG

GV20-0251

Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks

Trial Locations (1)

Unknown

West China Hospital, Chengdu